Skip to main content

Day: May 4, 2021

Dassault Aviation: Egypt acquires 30 additional Rafale fighters

Egypt acquires 30 additional Rafale fighters (Saint-Cloud, France, April 04, 2021) – The Arab Republic of Egypt has decided to purchase an additional 30 Rafales to equip its air force. This new order complements the first acquisition of 24 Rafales signed on February 2015 and will bring the number of Rafales flying under Egyptian colors to 54, making the Egyptian Air Force the second in the world after the French Air Force, to operate such a fleet of Rafales. It reflects the strategic relation between Egypt and France. It emphasizes also the confidence of the highest Egyptian authorities in Dassault Aviation and their satisfaction with the effective execution of the first contract. “This new order is proof of the unfailing bond that unites Egypt, the first foreign user of the Rafale, as it was for the Mirage 2000, with Dassault Aviation...

Continue reading

Breast Cancer Therapeutics Market Size 2021 | Is Projected to Reach USD 55.27 Billion by 2027 with a CAGR of 13.1%

Breast Cancer Therapeutics Market Key Players Studied in this Report are Genentech, Eli Lilly and Company, Novartis AG, AstraZeneca, Pfizer Inc., Sanofi, Eisai Co. Ltd., Kyowa Kirin, Bristol Myers Squibb, Merck & Co., Inc. and other key market players. Pune, India, May 04, 2021 (GLOBE NEWSWIRE) — According to the report, Breast Cancer Therapeutics market size is projected to reach USD 55.27 Billion by 2027. Breast Cancer Therapeutics Market was worth USD 21.58 billion in 2019 and will exhibit a CAGR of 13.1% during the forecast period. Nowadays, several renowned companies are constantly launching new breast cancer therapeutics worldwide. Most of these drugs are meant for the treatment of those types of breast cancers that were previously untreatable or the available drugs were not successful for providing positive outcomes. However,...

Continue reading

Share Buyback Transaction Details April 29 – May 3, 2021

Share Buyback Transaction Details April 29 – May 3, 2021 May 4, 2021 – Wolters Kluwer today reports that it has repurchased 64,630 of its own ordinary shares in the period from April 29, 2021, up to and including May 3, 2021, for €4.9 million and at an average share price of €75.45. The previously disclosed third-party agreement to repurchase shares for €70 million during the period starting February 26, 2021 up to and including May 3, 2021, has hereby been fulfilled. These repurchases are part of the share buyback program announced on February 24, 2021, under which we intend to repurchase shares for up to €350 million during 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021Period Cumulative shares repurchased in period Total consideration(€ million) Average...

Continue reading

Philips Foundation publishes its 2020 Annual Report highlighting the deployment of health technology expertise for underserved communities

philips-foundation-published- its-2020-annual-reportrapid-deployment-intensive-care-unit-in-bergamo-italyfostering-local-healthcare-innovation-in-kenyatransforming-primary-healthcare-ecosystems-from-the-inside-outMay 4, 2021 75 successful projects rolled out, including over 40 activities dedicated to combatting COVID-19 in 2020 Over 7.5 million people in underserved communities provided with access to healthcare in 2020 A global community of social entrepreneurs nurtured through development and scaling of sustainable models that provide affordable access to quality healthcareAmsterdam, the Netherlands – Philips Foundation, with its mission to provide access to quality healthcare for underserved communities through meaningful innovation, today announced publication...

Continue reading

On received court claim

On received court claim and adopted interim measures AB “Ignitis grupė” (hereinafter – the Company) informs that on 4 May 2021 it received information that Vilnius District Prosecutor’s Office (hereinafter – the Prosecutor) applied to Vilnius District Court (hereinafter – the Court) with a claim related to the decisions of the Company’s General Meeting of Shareholders and Management Board in respect of employee and executive incentive with share options plans implemented by the Company and invalidation of option agreements as well as request for application of interim measures (hereinafter – IM). IM were applied by the Court order on 3 May 2021, which, in principle, has suspended the employee stock ownership plan as well as executive long-term incentive with share options plan until the Court decision in respect of this case takes effect. According...

Continue reading

On received court claim and adopted interim measures

AB “Ignitis grupė” (hereinafter – the Company) informs that on 4 May 2021 it received information that Vilnius District Prosecutor’s Office (hereinafter – the Prosecutor) applied to Vilnius District Court (hereinafter – the Court) with a claim related to the decisions of the Company’s General Meeting of Shareholders and Management Board in respect of employee and executive incentive with share options plans implemented by the Company and invalidation of option agreements as well as request for application of interim measures (hereinafter – IM). IM were applied by the Court order on 3 May 2021, which, in principle, has suspended the employee stock ownership plan as well as executive long-term incentive with share options plan until the Court decision in respect of this case takes effect. According to the assessment of the Company, employee...

Continue reading

MT Højgaard Holding A/S: MT Højgaard Danmark wins turnkey contract for construction of office complex in Nordhavn

MT Højgaard Holding’s business unit, MT Højgaard Danmark, has been awarded a turnkey contract for the construction of a large office complex in Nordhavn in Copenhagen. The contract’s value amounts to DKK 1.589 billion. The turnkey contract includes project design and construction of an office complex of 56,500 square meters of floor space, which will serve as domiciles for AP Pension Livsforsikringsaktieselskab and Nykredit A/S as well as a multi-user house and common basement of 17,500 square meters. The developer is K/S Svanemølleholm, which is a company in the AP Pension group. Work will be initiated in May 2021, and the project will be completed in two phases. The construction work for Nykredit incl. basement has to be completed at the end of June 2023, and the domicile for AP Pension as well as the multi-user house have to be completed...

Continue reading

Proactive news headlines including Arrow Minerals, Archer Materials, MGC Pharmaceuticals and Meteoric Resources

Sydney, May 04, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Arrow Minerals Ltd (ASX:AMD) has received commitments from qualified sophisticated and professional investors to raise $3 million through the issue of 500 million shares at 6 cents per share. Click here Archer Materials Ltd’s (ASX:AXE) (OTCMKTS:ARRXF) (FRA:38A) shares are trading about 5% higher intra-day after executing a new quantum computing agreement with International Business Machines Corporation (NYSE:IBM). Click here MGC Pharmaceuticals Ltd (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) has received a new wholesale purchase order of ArtemiC Rescue from Swiss PharmaCan AG (SPC) worth about €640,000 (A$1 million). Click here Meteoric Resources NL (ASX:MEI) is...

Continue reading

Core One Labs Completes Milestone Acquisition of Akome Biotech

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has completed the acquisition (the “Transaction”) of Akome Biotech Ltd. (“Akome”). With this strategic acquisition, the scope of Core One’s psychedelics’ bio-pharma research and development division will broaden to include drug formulations that effectively target and change underlying processes at the root of neurological disorders, and/or prevent further neurological damage that result from the disorders. What distinguishes Akome’s approach from other companies focused on the psychedelic treatment of neurological...

Continue reading

Change in Enedo Plc’s Executive Management Team

ENEDO PLC   Stock Exchange Release     4.5.2021  at 9:45 Change in Enedo Plc’s Executive Management Team Olli Mustonen, Enedo’s Chief Financial Officer (CFO) and a member of the Executive Management Team, has resigned to move to new challenges outside Enedo. He will continue in his current position and as a member of the Executive Management Team for the time being, however, until the end of August 2021 at the latest. “Olli’s contribution to the changes in Enedo’s business operations and to the planning and implementation of financing activities over the past three years has been completely invaluable. Olli has been an integral part of planning and starting Enedo’s turnaround plan. I want to already now thank Olli for his excellent work and wish him success in the future with his own entrepreneurial path”,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.